skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Update on the role of modified release mesalamine in the management of ulcerative colitis and Crohn’s disease

Review

(2976) Views  (1023) Full article downloads

Authors: Glen A Doherty, Mark A Peppercorn

Published Date December 2009 Volume 2009:2 Pages 139 - 147
DOI: http://dx.doi.org/10.2147/CEG.S6145

Glen A Doherty, Mark A Peppercorn

Center for Inflammatory Bowel Disease, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston MA, USA

Abstract: 5-aminosalicyclates (5-ASA) remain a key first-line therapy for patients with ulcerative colitis (UC). A range of 5-ASA preparations is available and Eudragit-S® coated modified release formulations of mesalamine, such as Asacol®, remain among the most popular choices. We here review the current understanding of the mechanism of action of 5-ASA in inflammatory bowel disease. We evaluate evidence supporting the efficacy and safety of modified release mesalamine for both induction and remission maintenance in UC, including a review of the data from the recent ASCEND studies. We also examine the controversial issue of the role of mesalamine in treatment of Crohn’s disease (CD) and highlight data supporting its use following surgically induced remission of CD. Evidence supporting the use of mesalamine as prophylaxis for colorectal cancer and dysplasia will be considered. Finally, recent developments in our understanding of how to use modified release mesalamine in a safe and cost-effective manner are evaluated, including discussion of the importance of studying patient non-adherence as a key component of future studies in this area.

Keywords: mesalamine (mesalazine), 5-aminosalicyclate, ulcerative colitis, Crohn’s disease, modified release






 

Other articles by Dr Mark Peppercorn



Readers of this article also read:

Once daily versus conventional dosing of pH-dependent mesalamine long-term to maintain quiescent ulcerative colitis: Preliminary results from a randomized trial
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
An update on the use of pantoprazole as a treatment for gastroesophageal reflux disease
Health literacy and health seeking behavior among older men in a middle-income nation
Optimizing use of 5-ASA in the treatment of ulcerative colitis: Focus on patient compliance and adherence
Functional mobility and balance in community-dwelling elderly submitted to multisensory versus strength exercises
Solid self-nanoemulsifying cyclosporin A pellets prepared by fluid-bed coating: preparation, characterization and in vitro redispersibility
Perception of risk and benefit in patient-centered communication and care
Erratum
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
  • Testimonials

    "You do a tremendous job!!" Ruben Restrepo, The University of Texas Health Science Center at San Antonio